Which has stronger valuation and earnings, MLTX or ALXO?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is MLTX or ALXO more profitable?

MoonLake Immunotherapeutics' return on equity of -82.53% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -82.53% -58.17% ALX Oncology N/A -90.30% -67.28%

Which has preferable earnings and valuation, ANL or ALXO?

Adlai Nortye has higher revenue and earnings than ALX Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adlai Nortye $5M 202.73 -$35.53M N/A N/A ALX Oncology N/A N/A -$101.69M -$1.13 N/A

Is ANL or ALXO more profitable?

Adlai Nortye's return on equity of 0.00% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Adlai Nortye N/A N/A N/A ALX Oncology N/A -90.30% -67.28%

Is JANX or ALXO more profitable?

Janux Therapeutics' return on equity of -11.89% beat ALX Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Janux Therapeutics N/A -11.89% -11.13% ALX Oncology N/A -90.30% -67.28%

ALX Oncology (ALXO) Competitors

$1.70 -0.04 (-2.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.69 -0.01 (-0.59%)

As of 09/18/2026 07:30 PM Eastern

Compare

ALXO vs. MLTX, ANL, JANX, ABUS, and KURA

Should you buy ALX Oncology stock or one of its competitors? ALX Oncology's main competitors and comparable companies include MoonLake Immunotherapeutics (MLTX), Adlai Nortye (ANL), Janux Therapeutics (JANX), Arbutus Biopharma (ABUS), and Kura Oncology (KURA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ALX Oncology compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

MoonLake Immunotherapeutics' return on equity of -82.53% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
ALX Oncology	N/A	-90.30%	-67.28%

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 12.4% of ALX Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than ALX Oncology. MarketBeat recorded 3 mentions for MoonLake Immunotherapeutics and 0 mentions for ALX Oncology. MoonLake Immunotherapeutics' average media sentiment score of 1.04 beat ALX Oncology's score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
MoonLake Immunotherapeutics	Positive
ALX Oncology	Neutral

MoonLake Immunotherapeutics presently has a consensus price target of $24.57, suggesting a potential upside of 98.32%. ALX Oncology has a consensus price target of $4.60, suggesting a potential upside of 170.59%. Given ALX Oncology's stronger consensus rating and higher probable upside, analysts clearly believe ALX Oncology is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.44
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

ALX Oncology beats MoonLake Immunotherapeutics on 7 of the 13 factors compared between the two stocks.

How does ALX Oncology compare to Adlai Nortye?

Adlai Nortye (NASDAQ:ANL) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

35.2% of Adlai Nortye shares are held by institutional investors. Comparatively, 98.0% of ALX Oncology shares are held by institutional investors. 12.4% of ALX Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Adlai Nortye has higher revenue and earnings than ALX Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adlai Nortye	$5M	202.73	-$35.53M	N/A	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

In the previous week, Adlai Nortye had 2 more articles in the media than ALX Oncology. MarketBeat recorded 2 mentions for Adlai Nortye and 0 mentions for ALX Oncology. Adlai Nortye's average media sentiment score of 0.11 beat ALX Oncology's score of 0.00 indicating that Adlai Nortye is being referred to more favorably in the media.

Company	Overall Sentiment
Adlai Nortye	Neutral
ALX Oncology	Neutral

Adlai Nortye has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market.

Adlai Nortye presently has a consensus target price of $29.50, indicating a potential upside of 87.42%. ALX Oncology has a consensus target price of $4.60, indicating a potential upside of 170.59%. Given ALX Oncology's higher possible upside, analysts clearly believe ALX Oncology is more favorable than Adlai Nortye.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adlai Nortye	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Adlai Nortye's return on equity of 0.00% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adlai Nortye	N/A	N/A	N/A
ALX Oncology	N/A	-90.30%	-67.28%

Summary

Adlai Nortye beats ALX Oncology on 9 of the 12 factors compared between the two stocks.

How does ALX Oncology compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by insiders. Comparatively, 12.4% of ALX Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ALX Oncology has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$10M	101.43	-$113.62M	-$1.64	N/A
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

Janux Therapeutics' return on equity of -11.89% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
ALX Oncology	N/A	-90.30%	-67.28%

Janux Therapeutics has a beta of 2.53, indicating that its stock price is 153% more volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market.

In the previous week, Janux Therapeutics had 8 more articles in the media than ALX Oncology. MarketBeat recorded 8 mentions for Janux Therapeutics and 0 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 0.00 beat Janux Therapeutics' score of -0.03 indicating that ALX Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Janux Therapeutics	Neutral
ALX Oncology	Neutral

Janux Therapeutics currently has a consensus target price of $36.46, suggesting a potential upside of 119.78%. ALX Oncology has a consensus target price of $4.60, suggesting a potential upside of 170.59%. Given ALX Oncology's higher possible upside, analysts clearly believe ALX Oncology is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Janux Therapeutics and ALX Oncology tied by winning 7 of the 14 factors compared between the two stocks.

How does ALX Oncology compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and ALX Oncology (NASDAQ:ALXO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Arbutus Biopharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Comparatively, ALX Oncology has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market.

Arbutus Biopharma currently has a consensus price target of $5.00, indicating a potential downside of 0.20%. ALX Oncology has a consensus price target of $4.60, indicating a potential upside of 170.59%. Given ALX Oncology's stronger consensus rating and higher possible upside, analysts clearly believe ALX Oncology is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Arbutus Biopharma has higher revenue and earnings than ALX Oncology. ALX Oncology is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	70.49	-$33.50M	$0.79	6.34
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A

In the previous week, Arbutus Biopharma had 1 more articles in the media than ALX Oncology. MarketBeat recorded 1 mentions for Arbutus Biopharma and 0 mentions for ALX Oncology. Arbutus Biopharma's average media sentiment score of 1.72 beat ALX Oncology's score of 0.00 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Very Positive
ALX Oncology	Neutral

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 12.4% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to ALX Oncology's net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
ALX Oncology	N/A	-90.30%	-67.28%

Summary

Arbutus Biopharma beats ALX Oncology on 11 of the 15 factors compared between the two stocks.

How does ALX Oncology compare to Kura Oncology?

ALX Oncology (NASDAQ:ALXO) and Kura Oncology (NASDAQ:KURA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

ALX Oncology has higher earnings, but lower revenue than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.13	N/A
Kura Oncology	$67.48M	15.46	-$278.67M	-$3.37	N/A

In the previous week, Kura Oncology had 5 more articles in the media than ALX Oncology. MarketBeat recorded 5 mentions for Kura Oncology and 0 mentions for ALX Oncology. Kura Oncology's average media sentiment score of 0.34 beat ALX Oncology's score of 0.00 indicating that Kura Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
ALX Oncology	Neutral
Kura Oncology	Neutral

ALX Oncology has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

ALX Oncology currently has a consensus price target of $4.60, suggesting a potential upside of 170.59%. Kura Oncology has a consensus price target of $25.40, suggesting a potential upside of 116.54%. Given ALX Oncology's higher possible upside, equities research analysts plainly believe ALX Oncology is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Kura Oncology	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

98.0% of ALX Oncology shares are held by institutional investors. 12.4% of ALX Oncology shares are held by company insiders. Comparatively, 7.6% of Kura Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ALX Oncology has a net margin of 0.00% compared to Kura Oncology's net margin of -384.30%. ALX Oncology's return on equity of -90.30% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-90.30%	-67.28%
Kura Oncology	-384.30%	-207.18%	-45.17%

Summary

ALX Oncology beats Kura Oncology on 8 of the 15 factors compared between the two stocks.

Get ALX Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALXO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALXO vs. The Competition

Export

Metric	ALX Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$235.07M	$3.90B	$7.24B	$13.19B
Dividend Yield	N/A	3.64%	2.57%	12.81%
P/E Ratio	-1.50	14.23	275.49	25.40
Price / Sales	N/A	1,419.61	646.01	89.45
Price / Cash	N/A	108.90	76.25	51.42
Price / Book	3.54	15.45	10.46	6.33
Net Income	-$101.69M	-$22.86M	$3.49B	$358.33M
7 Day Performance	-12.37%	-1.21%	0.59%	1.12%
1 Month Performance	-14.57%	-3.29%	-1.74%	-2.39%
1 Year Performance	40.50%	37.74%	18.13%	5.35%

ALX Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALXO ALX Oncology	1.7574 of 5 stars	$1.70 -2.3%	$4.60 +170.6%	+40.5%	$235.07M	N/A	N/A	48	Analyst Upgrade High Trading Volume
MLTX MoonLake Immunotherapeutics	2.3972 of 5 stars	$12.10 -4.5%	$24.57 +103.0%	-77.0%	$1.03B	N/A	N/A	130	News Coverage Positive News Analyst Forecast
ANL Adlai Nortye	1.9845 of 5 stars	$15.90 -0.2%	$29.50 +85.5%	+804.1%	$1.02B	$18.06M	N/A	109
JANX Janux Therapeutics	2.8092 of 5 stars	$16.64 -3.9%	$36.46 +119.1%	-29.3%	$1.02B	$24M	N/A	113
ABUS Arbutus Biopharma	1.4527 of 5 stars	$5.07 -1.3%	$5.00 -1.3%	+17.9%	$1.00B	$14.08M	6.41	19	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALXO) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ALX Oncology (ALXO) Competitors

ALXO vs. MLTX, ANL, JANX, ABUS, and KURA

How does ALX Oncology compare to MoonLake Immunotherapeutics?

Summary

How does ALX Oncology compare to Adlai Nortye?

Summary

How does ALX Oncology compare to Janux Therapeutics?

Summary

How does ALX Oncology compare to Arbutus Biopharma?

Summary

How does ALX Oncology compare to Kura Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ALX Oncology (ALXO) Competitors

ALXO vs. MLTX, ANL, JANX, ABUS, and KURA

How does ALX Oncology compare to MoonLake Immunotherapeutics?

Is MLTX or ALXO more profitable?

Which has stronger valuation and earnings, MLTX or ALXO?

Do institutionals & insiders have more ownership in MLTX or ALXO?

Which has more risk & volatility, MLTX or ALXO?

Does the media refer more to MLTX or ALXO?

Do analysts rate MLTX or ALXO?

Summary

How does ALX Oncology compare to Adlai Nortye?

Do insiders & institutionals have more ownership in ANL or ALXO?

Which has preferable earnings and valuation, ANL or ALXO?

Does the media favor ANL or ALXO?

Which has more risk and volatility, ANL or ALXO?

Do analysts prefer ANL or ALXO?

Is ANL or ALXO more profitable?

Summary

How does ALX Oncology compare to Janux Therapeutics?

Do insiders and institutionals have more ownership in JANX or ALXO?

Which has higher valuation and earnings, JANX or ALXO?

Is JANX or ALXO more profitable?

Which has more risk and volatility, JANX or ALXO?

Does the media refer more to JANX or ALXO?

Do analysts recommend JANX or ALXO?

Summary

How does ALX Oncology compare to Arbutus Biopharma?

Which has more risk and volatility, ABUS or ALXO?

Do analysts prefer ABUS or ALXO?

Which has higher valuation & earnings, ABUS or ALXO?

Does the media favor ABUS or ALXO?

Do insiders & institutionals have more ownership in ABUS or ALXO?

Is ABUS or ALXO more profitable?

Summary

How does ALX Oncology compare to Kura Oncology?

Which has preferable valuation and earnings, ALXO or KURA?

Does the media prefer ALXO or KURA?

Which has more risk & volatility, ALXO or KURA?

Do analysts recommend ALXO or KURA?

Do institutionals and insiders have more ownership in ALXO or KURA?

Is ALXO or KURA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALXO vs. The Competition

ALX Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools